WO2002046368A1 - Liquide de conservation de cellules et procede de conservation de cellules dans lequel ledit liquide est utilise - Google Patents
Liquide de conservation de cellules et procede de conservation de cellules dans lequel ledit liquide est utilise Download PDFInfo
- Publication number
- WO2002046368A1 WO2002046368A1 PCT/JP2001/010389 JP0110389W WO0246368A1 WO 2002046368 A1 WO2002046368 A1 WO 2002046368A1 JP 0110389 W JP0110389 W JP 0110389W WO 0246368 A1 WO0246368 A1 WO 0246368A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- cell
- preservation solution
- cell preservation
- preservation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
Definitions
- the present invention relates to a cell preservation solution containing purified albumin and dimethyl sulfoxide and a method for preserving cells using the preservation solution, and aims to improve the percentage of revived effective cells after storage.
- Background technology :
- Cell preservation solutions and preservation methods are not uniform depending on the type of cells from which they are derived.
- cells such as microorganisms, generally 1
- the microorganisms are suspended in a culture medium for microorganisms containing about 0% glycerol and stored at low temperature, or the microorganisms themselves are stored in a lyophilized state.
- the cells are generally suspended in a culture solution containing fetal bovine serum supplemented with about 10% dimethyl sulfoxide, pre-cooled, and then placed in a liquid nitrogen storage. It is stored and saved.
- a phosphate buffer containing albumin alone is used as a preservative solution.
- a type containing serum for example, a serum containing dimethyl sulfoxide is contained in a culture solution.
- Cell preservatives are known.
- a serum-free type is known in which carboxymethylcellulose is contained in a cell preservation solution instead of serum (Japanese Patent Application Laid-Open No. 6-46840).
- a cell preservation solution containing serum is often used.
- a preservation solution for mammalian cells can be used to preserve microbial cells and germ cells, which are easier to preserve than mammalian cells. Also do It has been done.
- the serum-containing cell preservation solution contains not only various site-inducing factors and hormones as serum-containing components, but also amino acids and various ions.
- the properties of the preserved cells may be changed, and there is also the problem of the effects of unknown viruses that may be contained in serum. are doing.
- the properties of stored cells may be changed, the risk of contamination with unknown viruses, and the components of the preservation solution are unclear. It is difficult to ensure quality stability from the beginning.
- the present invention provides a cell preservation solution which does not contain both serum and culture solution, has clear components and has excellent cell preservation performance, and preservation of cells using the preservation solution. Disclosure of invention c to provide a method:
- the present invention provides a cell preservation solution containing purified albumin and dimethylsulfoxide.
- a purified albumin can be derived from the seaweed. It can also contain sugars in addition to purified albumin and dimethyl sulfoxide.
- the sugar may be a monosaccharide.
- the sugar in the cell preservation solution of the present invention may be glucose. It can contain phosphate ions in addition to purified albumin and dimethyl sulfoxide, or can contain metal ions in addition to purified albumin and dimethyl sulfoxide.
- the metal ion is a divalent metal ion. Is also good.
- the method for storing cells of the present invention uses a cell preservation solution as described above, suspends the cells in the cell preservation solution, dispenses the cells into a plurality of cell storage containers, and freeze-preserves them without preliminary freezing. I did it.
- Storage method of this cell the cell is stored aliquoted into cells coercive in presence container is suspended from 1 X 1 0 3 in cell preservation solution such that 1 X 1 0 8 or Z m 1 It can be stored frozen.
- serum-containing cell preservation solutions have the potential to change the properties of stored cells, and risk of contamination with unknown viruses, and because the components of the preservation solution are unclear, the quality is high. Since there are various problems such as difficulty in stabilizing, in the present invention, in order to avoid these problems altogether, both serum and culture medium are not included, and the components have clear and excellent cell storage performance. A cell preservation solution having the same and a cell preservation method using the preservation solution were developed, and various experiments were repeated.
- albumin contained in phosphate buffer which has been used to store germ cells
- Serum and culture medium-free cell preservation solution containing a mixture as the main agent and supplements such as phosphate ions, divalent metal ions, and monosaccharides as necessary
- the present inventors have found that they have excellent cell preservation performance for preserving microbial cells and germ cells, and have realized a cell preservation solution and a cell preservation method using the storage solution according to the present invention.
- the present invention is characterized in that the present invention contains purified albumin and dimethylsulfoxide as a cell preservation solution, and the dimethylsulfoxide used here is Generally known commercially available products can be used.
- the amount of dimethyl sulfoxide used when the concentration falls below 0.1% (wZw), the preservation capacity of Faint, and conversely 50 ° / with respect to the total volume of the storage solution. (w / w), the effect does not change, so from the viewpoint of effect and economy, it is within the range of 0.1% (w / w) to 50% (w / w), more preferably 1 to 50%. It is preferably in the range of 20% (w / w).
- albumin to be used in addition to dimethyl sulfoxide the type of albumin can be selected depending on the type of cells to be preserved.
- human albumin is used for preserving human cells for human treatment. Is best used.
- the present invention is not necessarily limited to this, and it is also possible to use those derived from pests or other species.
- albumin purified by any method can be used. Purified albumin can be used with a purity of about fraction V.
- the metal ions used in this case are various divalent or trivalent metal ions, and the use of divalent metal ions is particularly preferred. Other examples include calcium ions, magnesium ions, and iron ions. Use of ions, zinc ions, copper ions, aluminum ions, etc., can be considered.
- the use concentration may be very small, but if it is less than 0.001% (w / w), there is no effect, and conversely, if it exceeds 1% (w / w), it will not be effective. There is no change. Therefore, it is economical to use in a concentration range of 0.0 to 0.000 0 1 to 5% (w / w), more preferably in a concentration range of 0.1 to 5% (w / w). .
- sugar also improves the viable cell rate (effective cell rate) and the subsequent cultivation efficiency when cells are restored.
- the sugars used here include various monosaccharides such as glucose, galactose, fructose, ribose, trehalose, and pudose, disaccharides, and trisaccharides. Among them, glucose can be recommended in terms of economy and ease of handling.
- the amount of addition if the amount is less than 0.1% (w / w), there is no effect, and if the amount exceeds 10% (w / w), the effect does not change. w / w), more preferably 1 to 5% (w / w).
- phosphate ions can be used as a phosphate buffer, and Dulbecco's phosphate buffer, phosphate buffer and the like can be used.
- various culture solutions can be used in place of the divalent or trivalent metal ion phosphate buffer described above.
- the preservation of cells the cells were suspended in a tube for cryopreservation merely an example in cell preservation solution such that a LXL 0 3 and 1 x 1 0 8 pieces / m 1, this Store at 80 degrees Celsius or in liquid nitrogen. In this case, the temperature may be about 14 ° C. to 120 ° C. if storage is for a short period.
- cells can be suspended in the above-mentioned cell preservation solution, dispensed into a plurality of cell storage containers, and frozen and stored without preliminary freezing.
- the temperature of the cells suspended in the cell preservation solution can be gradually lowered by a program freezer or the like, but it is also possible to directly lower the temperature and store them.
- the cryopreserved cells are thawed at room temperature or in a constant temperature bath at 37 ° C, and then centrifuged using a centrifuge. Thereby, the cells and the cell preservation solution can be separated and restored. After the separated cells are washed with an appropriate culture solution or the like, they can be cultured by an ordinary method.
- the method for evaluating cell storage performance is as follows: cells are suspended in a cell preservation solution, frozen, and stored frozen for several hours to several days, and in some cases for several years, After returning the cryopreserved cells to room temperature, they can be cultured by counting the number of living cells at this time.
- P3U1 'cells derived from mouse myeloma were RPMI1640 + 7S (Niken Biomedical Research Institute, GM1104) in a carbon dioxide incubator for culture (Hirasa Corporation, CPD-300A).
- a medium containing 5 ml of O ml and fetal serum (Lifetech Oriental Co., Ltd., 26140-079) Is used as the culture medium, and the culture flask (Sumitomo Bakelite Co., Ltd.
- the number of cells the number of viable cells were 7. Ox 1 0 5 pieces Zml. Transfer each 5 Oml of the cell suspension to two centrifuge tubes (Nippon Becton Dickinson Co., Ltd., 2070), and centrifuge at 150 rpm for 10 minutes at 20 ° C (stock Company Kokusan, H700FR), P3U1 cells were precipitated. The supernatant is discarded by decantation, and the precipitated cells are uniformly loosened using a test tube mixer (Asahi Techno Glass Co., Ltd., MS-1) so that the cell concentration becomes 4.4 ⁇ 10 6 Zm 1.
- a cell preservative solution prepared in [1] was suspended so that the cells become uniform, serum tubes (manufactured by Asahi Techno glass Corporation, 2722002) as the total number of cells becomes 4. 4x1 0 6 cells / tube Dispensed. Then, it was placed in a black (Asahi Techno Glass Co., Ltd., 9791-081) and stored at 180 ° C freezer (Sanyo Electric Co., Ltd., MDF-382).
- the K562 cells which are cells derived from human leukemia, [2.] and cultured Ri by the same operation, was counted the number of cells, cell number is the number of viable cells 7.
- the present invention contains purified albumin and dimethyl sulfoxide as a cell preservation solution, and to which auxiliary agents such as phosphate ions, divalent metal ions, and monosaccharides are added as necessary.
- auxiliary agents such as phosphate ions, divalent metal ions, and monosaccharides are added as necessary.
- a self-prepared cell preservation medium as a preservation medium for other cells, and, like a cell preservation medium containing serum
- a culture solution containing many components that are not essential for cell preservation, such as amino acids and various ions, in addition to various site components, growth factors, hormones, etc. as serum-containing components.
- there is no danger of changing the properties of the cells by using a different culture solution for each cell to be cultured, or allowing the contamination of unknown viruses, and in addition, There is no need to use the Kuchi' door of serum.
- the cell preservation solution of the present invention is particularly suitable for storing mammalian cells, but can also be used for storing protoplasts and other plant cells and germ cells. Furthermore, various cell banks can be efficiently constructed using the cell preservation solution of the present invention.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU18486/02A AU1848602A (en) | 2000-12-04 | 2001-11-28 | Cell-preservation liquid and method of preserving cells by using the liquid |
CA002399423A CA2399423A1 (en) | 2000-12-04 | 2001-11-28 | Cell-preservation liquid and method for preserving cells by using the liquid |
DE60116673T DE60116673T2 (de) | 2000-12-04 | 2001-11-28 | Zellkonservierungsflüssigkeit und verfahren zur zellkonservierung mit dieser flüssigkeit |
EP01999633A EP1347040B1 (en) | 2000-12-04 | 2001-11-28 | Cell-preservation liquid and method of preserving cells by using the liquid |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-368290 | 2000-12-04 | ||
JP2000368290 | 2000-12-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002046368A1 true WO2002046368A1 (fr) | 2002-06-13 |
Family
ID=18838570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/010389 WO2002046368A1 (fr) | 2000-12-04 | 2001-11-28 | Liquide de conservation de cellules et procede de conservation de cellules dans lequel ledit liquide est utilise |
Country Status (8)
Country | Link |
---|---|
US (1) | US20030013074A1 (ja) |
EP (1) | EP1347040B1 (ja) |
CN (1) | CN1230524C (ja) |
AT (1) | ATE315635T1 (ja) |
AU (1) | AU1848602A (ja) |
CA (1) | CA2399423A1 (ja) |
DE (1) | DE60116673T2 (ja) |
WO (1) | WO2002046368A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1471140A4 (en) * | 2002-01-31 | 2005-02-16 | Asahi Techno Glass Cosporation | LIQUIDITY FOR DEEP-FREEZE STORAGE OF EMBRYONIC PRIMATIVE STEM CELLS AND DEEP-FREEZE STORAGE PROCESS |
EP1647186A1 (en) * | 2004-10-12 | 2006-04-19 | Nipro Corporation | Cell-preservation liquid |
US8628960B2 (en) | 2007-09-24 | 2014-01-14 | Hememics Biotechnologies, Inc. | Desiccated biologics and methods of preparing the same |
US9943075B2 (en) | 2010-02-17 | 2018-04-17 | Hememics Biotechnologies, Inc. | Preservation solutions for biologics and methods related thereto |
CN111718908A (zh) * | 2020-08-11 | 2020-09-29 | 杭州博日科技有限公司 | 病毒样本保存液及其制备方法和应用 |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100425693C (zh) * | 2004-02-16 | 2008-10-15 | 瑞德肝脏疾病研究(上海)有限公司 | 一种保存体外肝细胞系统的方法 |
EP1820847B1 (en) | 2004-09-24 | 2014-06-11 | Seiren Kabushiki Kaisha | Composition for cell frozen-storage |
CN101672853B (zh) * | 2009-09-28 | 2014-11-05 | 江西特康科技有限公司 | 血细胞分析仪校准品及其制备工艺 |
JP6142142B2 (ja) * | 2012-04-10 | 2017-06-07 | 株式会社リンフォテック | メモリーt細胞を主成分とするリンパ球細胞群の製造方法 |
CN112806352A (zh) * | 2013-03-15 | 2021-05-18 | 特拉基应用基因组学有限责任公司 | 用于保持已手术去除的组织中的癌细胞活力的方法和试剂 |
CN107779432A (zh) * | 2016-08-29 | 2018-03-09 | 灏灵赛奥(天津)生物科技有限公司 | 一种car‑t细胞制剂及低温保存介质 |
CN108235981B (zh) * | 2016-12-23 | 2021-07-23 | 西比曼生物科技(香港)有限公司 | 一种可临床使用的细胞冻存液 |
CN106993606A (zh) * | 2017-04-20 | 2017-08-01 | 苏州新赛美生物科技有限公司 | 一种不含蛋白和血清的细胞冻存液及其制备方法 |
CN107646831A (zh) * | 2017-11-13 | 2018-02-02 | 重庆斯德姆生物技术有限公司 | 一种用于mcf‑7乳腺癌细胞的冻存液 |
CN107926930A (zh) * | 2017-11-22 | 2018-04-20 | 瑞柏生物(中国)股份有限公司 | 一种精子冷冻液及其制备方法 |
CN107996558A (zh) * | 2017-12-21 | 2018-05-08 | 湖南丰晖生物科技有限公司 | 细胞冻存液及其应用 |
CN113056556A (zh) * | 2018-08-31 | 2021-06-29 | 学校法人同志社 | 用于对眼细胞进行保存或培养的组合物以及方法 |
CN109349270A (zh) * | 2018-11-09 | 2019-02-19 | 合肥诺森医学检验有限公司 | 细胞保存液及使用细胞保存液保存细胞的方法 |
CN109497043A (zh) * | 2018-12-28 | 2019-03-22 | 中国医学科学院整形外科医院 | 无血清纳米材料冻存剂及其制备方法、使用方法,冻存液 |
CN109907036A (zh) * | 2019-02-27 | 2019-06-21 | 北京益华生物科技有限公司 | 细胞冻存液、细胞冻存液制备方法和细胞冻存方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0646840A (ja) * | 1992-08-04 | 1994-02-22 | Nippon Zenyaku Kogyo Kk | 細胞凍結保存液 |
JPH07255469A (ja) * | 1994-03-17 | 1995-10-09 | Kurabo Ind Ltd | 動物細胞の凍結保存液 |
JP2000201672A (ja) * | 1999-01-11 | 2000-07-25 | Asahi Medical Co Ltd | 有核細胞の凍結保存用組成物 |
JP2001354575A (ja) * | 2000-06-09 | 2001-12-25 | Human Tekku:Kk | 癌の再発予防法および癌の再発予防用活性化リンパ球を含む製剤、ならびにそれらの細胞の凍結および加工委・受託システム |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4004975A (en) * | 1975-12-30 | 1977-01-25 | The United States Of America As Represented By The Secretary Of The Navy | Method of isolating and cryopreserving human white cells from whole blood |
JPH07500597A (ja) * | 1991-10-23 | 1995-01-19 | セルプロ インコーポレイテッド | 移植用細胞の冷凍方法 |
WO1995010291A1 (en) * | 1993-10-08 | 1995-04-20 | Cellpro Ii | Methods for collection and cryopreservation of human granulocytes |
AU4751697A (en) * | 1996-10-10 | 1998-05-05 | Douglas Danner | Animal cell culture media comprising plant-derived nutrients |
US6485959B1 (en) * | 1998-10-07 | 2002-11-26 | Cedars Sinai Medical Center | Cell preconditioning and cryopresevation medium |
US6060252A (en) * | 1999-04-12 | 2000-05-09 | Becton Dickinson And Company | Amplification and detection of shigella spp. and enteroinvasive strains of Escherichia coli |
-
2001
- 2001-11-28 EP EP01999633A patent/EP1347040B1/en not_active Expired - Lifetime
- 2001-11-28 AU AU18486/02A patent/AU1848602A/en not_active Abandoned
- 2001-11-28 AT AT01999633T patent/ATE315635T1/de not_active IP Right Cessation
- 2001-11-28 CN CN01804458.1A patent/CN1230524C/zh not_active Expired - Fee Related
- 2001-11-28 WO PCT/JP2001/010389 patent/WO2002046368A1/ja active IP Right Grant
- 2001-11-28 US US10/182,908 patent/US20030013074A1/en not_active Abandoned
- 2001-11-28 DE DE60116673T patent/DE60116673T2/de not_active Expired - Lifetime
- 2001-11-28 CA CA002399423A patent/CA2399423A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0646840A (ja) * | 1992-08-04 | 1994-02-22 | Nippon Zenyaku Kogyo Kk | 細胞凍結保存液 |
JPH07255469A (ja) * | 1994-03-17 | 1995-10-09 | Kurabo Ind Ltd | 動物細胞の凍結保存液 |
JP2000201672A (ja) * | 1999-01-11 | 2000-07-25 | Asahi Medical Co Ltd | 有核細胞の凍結保存用組成物 |
JP2001354575A (ja) * | 2000-06-09 | 2001-12-25 | Human Tekku:Kk | 癌の再発予防法および癌の再発予防用活性化リンパ球を含む製剤、ならびにそれらの細胞の凍結および加工委・受託システム |
Non-Patent Citations (4)
Title |
---|
HIROAKI KASAI ET AL.: "Straw cut ho ni yoru ushi taigai jusei yurai hai no glasska toketsu", BULLETIN OF THE STUDIES OF TOKUSHIMA PRIFECTUAL LIVESTOCK EXPERIMENT STATION, vol. 41, November 2000 (2000-11-01), pages 1 - 6, XP002951071 * |
HIROSHI KANO ET AL.: "Golden hamster mijuseiran no toketsu yukaigo no seizonsei ni tsuite", JOURNAL OF MAMMALIAN OVA RESEARCH, vol. 6, no. 1, April 1989 (1989-04-01), pages 79 - 80, XP002951072 * |
LUSCINSKAS F.W. ET AL.: "Long-term cryopreservation of dog granulocytes", CRYOBIOLOGY, vol. 20, no. 1, 1983, pages 1 - 6, XP002909463 * |
VAN DER ELST J. ET AL.: "The effect of equilibration temperature and time on the outcome of ultrarapid freezing of 1-cell mouse embryos", HUM. REPROD., vol. 10, no. 2, 1995, pages 379 - 383, XP002909462 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1471140A4 (en) * | 2002-01-31 | 2005-02-16 | Asahi Techno Glass Cosporation | LIQUIDITY FOR DEEP-FREEZE STORAGE OF EMBRYONIC PRIMATIVE STEM CELLS AND DEEP-FREEZE STORAGE PROCESS |
EP1647186A1 (en) * | 2004-10-12 | 2006-04-19 | Nipro Corporation | Cell-preservation liquid |
US8628960B2 (en) | 2007-09-24 | 2014-01-14 | Hememics Biotechnologies, Inc. | Desiccated biologics and methods of preparing the same |
US9642353B2 (en) | 2007-09-24 | 2017-05-09 | Hememics Biotechnologies, Inc. | Desiccated biologics and methods of preparing the same |
US9943075B2 (en) | 2010-02-17 | 2018-04-17 | Hememics Biotechnologies, Inc. | Preservation solutions for biologics and methods related thereto |
CN111718908A (zh) * | 2020-08-11 | 2020-09-29 | 杭州博日科技有限公司 | 病毒样本保存液及其制备方法和应用 |
CN111718908B (zh) * | 2020-08-11 | 2022-05-24 | 杭州博日科技股份有限公司 | 病毒样本保存液及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
EP1347040B1 (en) | 2006-01-11 |
US20030013074A1 (en) | 2003-01-16 |
DE60116673T2 (de) | 2006-08-10 |
CN1230524C (zh) | 2005-12-07 |
CA2399423A1 (en) | 2002-06-13 |
EP1347040A4 (en) | 2004-10-27 |
ATE315635T1 (de) | 2006-02-15 |
DE60116673D1 (de) | 2006-04-06 |
EP1347040A1 (en) | 2003-09-24 |
AU1848602A (en) | 2002-06-18 |
CN1396951A (zh) | 2003-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002046368A1 (fr) | Liquide de conservation de cellules et procede de conservation de cellules dans lequel ledit liquide est utilise | |
Thirumala et al. | Clinical grade adult stem cell banking | |
AU2003238620B2 (en) | Liquid for frozen storage of primate embryo stem cells and frozen storage method | |
JP6850360B2 (ja) | 臨床使用可能な細胞凍結保存液 | |
Sasnoor et al. | Supplementation of conventional freezing medium with a combination of catalase and trehalose results in better protection of surface molecules and functionality of hematopoietic cells | |
US9617515B2 (en) | Non-embryonic totipotent blastomere-like stem cells and methods therefor | |
JP2008501320A (ja) | 細胞保存方法 | |
CA3046169C (en) | Mammalian cell cryopreservation liquid | |
JPWO2018084228A1 (ja) | 動物細胞又は動物組織の凍結保存用溶液、凍結物、及び凍結保存方法 | |
Campos et al. | Definition of optimal conditions for collection and cryopreservation of umbilical cord hematopoietic cells | |
KR102391629B1 (ko) | 펙틴과 알라닌을 이용한 세포 동결 보존용 조성물 및 이를 이용한 세포 동결 보존 방법 | |
CN110637810A (zh) | 一种临床级树突状细胞冻存液 | |
JP4385158B2 (ja) | 細胞の保存液および該保存液を用いた細胞の保存方法 | |
Di et al. | Development and evaluation of a trehalose‐contained solution formula to preserve HUC‐MSCs at 4 C | |
Riau et al. | Isolation and propagation of human corneal stromal keratocytes for tissue engineering and cell therapy | |
EP0647267B1 (en) | Stem cell storage | |
JP2022131878A (ja) | 凍結された腎臓細胞の製造方法及び凍結された腎臓細胞 | |
KR20180109600A (ko) | 동결보존효과가 개선된 줄기세포 동결보존용 조성물 및 이를 이용한 방법 | |
Munévar et al. | Evaluation of two human dental pulp stem cell cryopreservation methods | |
JP2014183825A (ja) | 再生医療に資するヒトiPS細胞(人工多能性幹細胞)由来の心筋細胞あるいはヒト心筋細胞を安定的に大量培養して保存する方法に関する。 | |
Anagnostakis et al. | Successful short‐term cryopreservation of volume‐reduced cord blood units in a cryogenic mechanical freezer: effects on cell recovery, viability, and clonogenic potential | |
Lionetti et al. | Factors affecting the stability of cryogenically preserved granulocytes | |
JPS63216476A (ja) | 無血清凍結保存用培地 | |
CN114762497B (zh) | 细胞冻存液及细胞冻存方法 | |
JP2008104407A (ja) | 細胞保存方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18486/02 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10182908 Country of ref document: US Ref document number: 018044581 Country of ref document: CN Ref document number: 2399423 Country of ref document: CA |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001999633 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001999633 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001999633 Country of ref document: EP |